AspenBio Pharma inks worldwide license agreement for its animal health assets
CASTLE ROCK – AspenBio Pharma Inc. (Nasdaq: APPY) announced it has executed an exclusive worldwide license agreement with a major international animal health company, providing license and sub-license...
View ArticleAspenBio Pharma seeks name change to Vanaxis
CASTLE ROCK – AspenBio Pharma Inc. (Nasdaq: APPY) will ask its stockholders to approve changing its name to Vanaxis Inc., the company announced. AspenBio, an in vitro diagnostic company, said the name...
View ArticleAspenBio Pharma earns $3.7 million in stock sale to help fund clinical trial
CASTLE ROCK – AspenBio Pharma Inc. (Nasdaq: APPY) announced it closed on a public offering of 1,946,000 shares of its common stock at a price of $2.10 per share. After expenses, the company said it...
View ArticleAspenBio Pharma changes its name to Venaxis
CASTLE ROCK – Venaxis Inc. (Nasdaq: APPY) – formerly AspenBio Pharma – has changed its corporate name after a recent meeting of its shareholders, the company announced. The company’s common stock will...
View ArticleVenaxis files for CE Mark approval for European commercialization
CASTLE ROCK – Venaxis Inc. (Nasdaq: APPY) has filed for CE Mark approval in Europe for APPY 1, its blood-based appendicitis test, the company announced. Venaxis said it expects to obtain CE Mark...
View ArticleVenaxis obtains CE Mark for APPY1 appendicitis test
CASTLE ROCK – Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company, has fulfilled the requirements for CE Marking in Europe for its APPY1 blood-based appendicitis test, the company announced....
View ArticleVenaxis signs agreement with European distributor, gets first APPY1 order
CASTLE ROCK – Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA approval for its blood-based appendicitis test, announced it has signed its first European commercial...
View ArticleVenaxis expands European distribution network for APPY1 appendicitis test
CASTLE ROCK – Venaxis Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on gaining FDA approval and commercialization of its APPY1 appendicitis test, announced it has signed agreements with...
View ArticleVenaxis closes public stock offering, raises $14.4 million for APPY1
CASTLE ROCK – Venaxis Inc. (Nasdaq: APPY) announced it has closed its underwritten public offering that resulted in the sale of 11.5 million shares of common stock and gross proceeds of $14.4 million.
View Article
